Well Daan Van Sells 2,400 Shares of SOPHiA GENETICS (NASDAQ:SOPH) Stock

April 15, 2026 by InsiderTrades.com

Key Points

Well Daan Van sold 2,400 SOPHiA GENETICS shares on April 10 at an average price of $4.67 under a pre-arranged Rule 10b5-1 plan to cover tax withholding, leaving him with 346,420 shares (a 0.69% reduction, valued at about $1.62M).
Company insiders collectively sold roughly 43,400 shares on April 10 and 13—including CEO Jurgi Camblong's ~16,631 shares—with all transactions executed under 10b5-1 plans and described as tax-related for vested awards.
SOPH has a market cap of about $340M and recently reported a quarterly loss (EPS -$0.28, missing estimates) with negative margins, while analysts' consensus is a “Hold” and an average price target of $7.00.

SOPHiA GENETICS SA (NASDAQ:SOPH - Get Free Report) insider Well Daan Van sold 2,400 shares of SOPHiA GENETICS stock in a transaction dated Friday, April 10th. The shares were sold at an average price of $4.67, for a total value of $11,208.00. Following the transaction, the insider owned 346,420 shares of the company's stock, valued at $1,617,781.40. This trade represents a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Well Daan Van also recently made the following trade(s):

On Thursday, April 9th, Well Daan Van sold 1,988 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.74, for a total value of $9,423.12.
On Wednesday, April 8th, Well Daan Van sold 2,861 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $13,875.85.
On Monday, April 6th, Well Daan Van sold 2,705 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.86, for a total value of $13,146.30.
On Thursday, March 19th, Well Daan Van sold 684 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $3,276.36.

SOPHiA GENETICS Price Performance

SOPH stock opened at $4.96 on Wednesday. The company has a market capitalization of $339.71 million, a P/E ratio of -9.73 and a beta of 1.04. The company has a debt-to-equity ratio of 1.01, a quick ratio of 1.84 and a current ratio of 1.96. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The business has a 50-day simple moving average of $4.74 and a two-hundred day simple moving average of $4.72.

SOPHiA GENETICS (NASDAQ:SOPH - Get Free Report) last released its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.08). The company had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. Research analysts expect that SOPHiA GENETICS SA will post -0.96 EPS for the current fiscal year.

Hedge Funds Weigh In On SOPHiA GENETICS

A number of hedge funds and other institutional investors have recently modified their holdings of SOPH. Savvy Advisors Inc. purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $48,000. Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $54,000. Finally, XTX Topco Ltd purchased a new position in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company's stock.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

Neutral Sentiment: Aggregate insider activity: company executives and other insiders sold a combined ~43,400 shares across transactions on April 10 and April 13. Sales were executed under pre-arranged Rule 10b5-1 plans and were reported in SEC Form 4 filings. SEC Form 4
Neutral Sentiment: CEO Jurgi Camblong sold 12,232 shares on April 10 and 4,399 shares on April 13 (total ~16,631 shares). Trades were made under a 10b5-1 plan to cover tax withholding tied to equity vesting; his remaining direct stake remains large (>3.7M shares). SEC Form 4
Neutral Sentiment: President Ross Muken sold 3,687 shares on April 10 and 4,442 shares on April 13 (~8,129 shares). Transactions were under a 10b5-1 plan and described as tax-related for vested awards. SEC Form 4
Neutral Sentiment: Other insiders (Philippe Menu and Zhenyu Xu) each made paired sales on April 10 and April 13 totaling ~8,125 and ~8,120 shares respectively; Well Daan Van sold 2,400 shares on April 10. All trades were 10b5-1, tax-withholding sales. SEC Form 4 (Menu) SEC Form 4 (Xu) SEC Form 4 (Van)

Analysts Set New Price Targets

SOPH has been the topic of a number of research analyst reports. Guggenheim boosted their target price on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a "buy" rating in a research note on Monday, January 26th. Weiss Ratings restated a "sell (d-)" rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, BTIG Research restated a "buy" rating and issued a $7.00 target price on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Two analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $7.00.

Check Out Our Latest Research Report on SOPH

About SOPHiA GENETICS

(Get Free Report)

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.